GreenPeptide Co., Ltd. announced that its Investigational New Drug (IND) application for a Phase 1 clinical study with a therapeutic cancer vaccine GRN-1201 has been cleared by the United States Food and Drug Administration (FDA). GRN-1201 will be tested in patient with melanoma. The GRN-1201 cancer vaccine is a combination of four HLAA 02 restricted peptides derived from four separate tumor associated antigens presented in cancer cells and required by cancer cells to grow and survive.

Assuming future out-license to multinational pharmaceutical companies, the Phase 1 study will be conducted as GRN-1201 monotherapy in patients with malignant melanoma as an initial indication, followed by clinical trials in combination with other cancer immunotherapies, especially with immune checkpoint inhibitors, and for additional indications in the future.